<DOC>
	<DOCNO>NCT02317874</DOCNO>
	<brief_summary>This phase I trial study side effect best dose talazoparib give together carboplatin paclitaxel treat patient solid tumor spread place body remove surgery . Talazoparib may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , carboplatin paclitaxel , work different way stop growth tumor cell , either kill cell , stop dividing , stop spread . Giving talazoparib carboplatin paclitaxel may kill tumor cell .</brief_summary>
	<brief_title>Talazoparib , Carboplatin , Paclitaxel Treating Patients With Solid Tumors That Are Metastatic Can Be Removed Surgery</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximum tolerate dose ( MTD ) recommend phase 2 dose ( RP2D ) BMN 673 ( talazoparib ) seven day schedule combination carboplatin paclitaxel . II . To determine maximum tolerate dose ( MTD ) recommend phase 2 dose ( RP2D ) BMN 673 three day schedule combination carboplatin paclitaxel . SECONDARY OBJECTIVES : I . To observe record anti-tumor activity BMN 673 combination carboplatin paclitaxel . II . To determine whether pharmacokinetic parameter BMN 673 give combination carboplatin paclitaxel correlate thrombocytopenia . III . To observe record anti-tumor activity BMN 673 alone combination carboplatin , paclitaxel BMN673 . IV . To observe safety tolerability BMN 673 combination paclitaxel carboplatin BMN 673 alone combination therapy . TERTIARY OBJECTIVES : I . To serially evaluate pharmacokinetic pharmacodynamics parameter use indirect pharmacokinetic/pharmacodynamics model correlate tumor response resistance combination BMN 673 , carboplatin , paclitaxel therapy . II . To explore mechanism resistance combination BMN 673 carboplatin paclitaxel . OUTLINE : This dose-escalation study talazoparib . Patients assign 1 2 dosing schedule . SCHEDULE A : Patients receive talazoparib orally ( PO ) daily ( QD ) day 1-7 , paclitaxel intravenously ( IV ) 1 hour day 1 , 8 , 15 , carboplatin IV 30 minute day 1 . Treatment repeat every 21 day 4-6 course absence disease progression unacceptable toxicity . SCHEDULE B : Patients receive talazoparib PO QD day 1-3 , paclitaxel IV 1 hour day 1 , 8 , 15 , carboplatin IV 30 minute day 1 . Treatment repeat every 21 day 4-6 course absence disease progression unacceptable toxicity . At time 4-6 course treatment , patient may continue combination study therapy talazoparib , carboplatin , paclitaxel , talazoparib carboplatin , talazoparib alone ( continuous dosing ) , observation without therapy discretion treat physician . After completion study treatment , patient follow 4 week .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Talazoparib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Patients must histologically confirm solid malignancy ( exclude lymphoma ) metastatic unresectable standard curative measure exist longer effective , : ) reasonable expectation response combination carboplatin/paclitaxel OR b ) breast cancer ( BRCA ) 1/2 germline mutation present ; result Myriad acceptable ; test BRCA 1 2 germline mutation do another organization , report genetics consult qualified medical professional confirm laboratory result show recognize germline deleterious BRCA 1 2 mutation rearrangement require ; latter obtain , principal investigator ( PI ) study chair review lab result confirmation BRCA mutation rearrangement require OR c ) BRCA 1/2 somatic mutation previously identify use Clinical Laboratory Improvement Amendments ( CLIA ) certify assay Patients must measurable evaluable disease , define Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 2 ( Karnofsky &gt; = 60 % ) Life expectancy great 12 week Absolute neutrophil count &gt; = 1,500/mcL Hemoglobin &gt; = 9 g/dL Platelets &gt; = 150,000/mcL Total bilirubin = &lt; 1.25 x institutional upper limit normal ( ULN ) , exception &lt; 2.9 mg/dL patient Gilbert 's disease Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) /alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) = &lt; 2.5 x ULN ; = &lt; 5 x ULN set metastatic liver disease Creatinine = &lt; 1.5 x upper limit normal OR creatinine clearance &gt; = 50 mL/min Ability take oral medication Patients central nervous system ( CNS ) metastases must stable therapy CNS metastasis ( surgery , radiotherapy stereotactic radiosurgery ) least 3 month must steroid treatment 2 week prior study enrollment Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation ; woman become pregnant suspect pregnant partner participate study , inform treat physician immediately ; men treat enrolled protocol must also agree use adequate contraception prior study , duration study participation , 4 month completion BMN 673 administration Ability understand willingness sign write informed consent document Patients chemotherapy radiotherapy within 4 week ( 6 week nitrosoureas mitomycin C ) target therapy within 2 week prior enter study recover ( = &lt; grade 1 ) adverse event due agent administer exception grade alopecia No prior carboplatin unless give neoadjuvant/adjuvant set curative intent 6 month elapse since last carboplatin dose ; case relapse ovarian cancer , patient eligible 6 month elapse since last carboplatin dose Patients receive investigational agent History allergic reaction attribute compound similar chemical biologic composition BMN 673 agent use study Peripheral neuropathy severity great grade 1 The following medication contraindicate must use caution Contraindicated : Cytochrome P450 , family 2 , subfamily C , polypeptide 8 ( CYP2C8 ) strong moderate inhibitor CYP2C8 inducer Cytochrome P450 , family 3 , subfamily A , polypeptide 4 ( CYP3A4 ) strong moderate inhibitor CYP3A4 inducer CYP3A4 sensitive substrate Exclusions : follow supportive care medication allow : dexamethasone , aprepitant , fosaprepitant , ondansetron ; oral pain medication hydrocodone , oxycodone take needed basis also permit ; transdermal product design systemic delivery must assess interaction potential ; topical product design provide systemic delivery ( include inhale product , ophthalmologic product transvaginal preparation ) need consider since appreciable systemic absorption Other contraindicated medication ( per ) allow unless close monitoring labs drug level dose adjustment feasible ; patient take concurrent medication ineligible unless discontinue switch alternative medication prior initiation study drug ( least 5 halflives ) Use caution : CYP2C8 sensitive substrate CYP2C8 weak inhibitor CYP3A4 nonsensitive substrate CYP3A4 weak inhibitor These agent may permit discontinuation feasible acceptable alternative available determine treat physician ; however , caution use ; consider monitor labs drug level dose adjustment medication Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Pregnant woman exclude study ; breastfeed discontinue mother treated BMN 673 Human immunodeficiency virus ( HIV ) positive patient combination antiretroviral therapy ineligible No clinically significant bleeding ( i.e . gastrointestinal [ GI ] bleed , intracranial bleeding ) within 6 month major surgery within 4 week ; minor surgery ( i.e . port placement , cataract surgery ) allow within 2 week Anticoagulation antiplatelet therapy permit ( include Coumadin , low molecular weight heparin , factor Xa inhibitor , aspirin nonsteroidal antiinflammatory drug [ NSAIDS ] medicine similar effect )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>